ArQule (ARQL) Misses Q1 EPS by 1c, Revenues Miss; Affirms 2Q EPS/Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
ArQule (ARQL) PT Raised to $9 at Needham & Company
May 1, 2019 11:28 AM EDTNeedham & Company analyst Chad Messer raised the price target on ArQule (NASDAQ: ARQL) to $9.00 (from $7.00) while maintaining a Buy rating.
The analyst commented, :ArQule is currently enrolling a 75 mg dose cohort (cohort 8) in the Phase I study of ARQ531. A... More
ArQule (ARQL) PT Raised to $10 at Roth Capital
April 29, 2019 7:51 AM EDTRoth Capital analyst Jotin Marango raised the price target on ArQule (NASDAQ: ARQL) to $10.00 (from $8.00) while maintaining a Buy rating.
The analyst comments "This spring, we are increasingly bullish on ArQule, following the material advance of the underappeciated Proteus/PROS program in... More
